Cresset Asset Management LLC Has $449,000 Stock Holdings in Illumina, Inc. $ILMN

Cresset Asset Management LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 19.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,656 shares of the life sciences company’s stock after buying an additional 919 shares during the period. Cresset Asset Management LLC’s holdings in Illumina were worth $449,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brown Advisory Inc. boosted its position in Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Illumina by 2,057.5% during the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company’s stock valued at $73,174,000 after purchasing an additional 879,533 shares during the last quarter. Vanguard Group Inc. boosted its position in Illumina by 3.5% during the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock valued at $1,298,928,000 after purchasing an additional 558,243 shares during the last quarter. Pacer Advisors Inc. boosted its position in Illumina by 2,292.9% during the first quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company’s stock valued at $44,881,000 after purchasing an additional 542,040 shares during the last quarter. Finally, Spyglass Capital Management LLC acquired a new stake in Illumina during the fourth quarter valued at $71,855,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

NASDAQ ILMN opened at $101.80 on Monday. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock’s 50-day moving average is $98.18 and its two-hundred day moving average is $88.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market cap of $15.65 billion, a P/E ratio of 12.89, a price-to-earnings-growth ratio of 2.29 and a beta of 1.37.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Stephens set a $110.00 price objective on Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective for the company. in a research report on Friday, July 11th. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Royal Bank Of Canada lifted their price objective on Illumina from $118.00 to $126.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Finally, Morgan Stanley lifted their price objective on Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, August 4th. Seven analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average price target of $124.58.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.